Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis
In the United States (US), meningococcal serogroup B (MenB) vaccination has been recommended for 16–23-year-olds (preferably 16–18 years) based on shared clinical decision-making since 2015. MenB vaccine coverage (≥1 dose) by age 17 years has been reported, but initiation at older ages and by insura...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2165382 |